Understanding the QuantiFERON-TB Gold Test and Screening Results

What Is the QuantiFERON-TB Gold Test?

The QuantiFERON-TB Gold test is an in vitro diagnostic blood test that measures cell-mediated immune reactivity to tuberculosis antigens. The test belongs to a class of diagnostics called interferon-gamma release assays. Instead of introducing foreign antigens into the patient's body, the laboratory introduces synthetic tuberculosis proteins to a collected blood sample inside sealed tubes. Specialized white blood cells called T-lymphocytes release a signaling cytokine called interferon-gamma when they recognize antigens they have encountered during a past infection.

The laboratory measures the concentration of this cytokine to determine whether the immune system shows sensitization to Mycobacterium tuberculosis. Because the test operates in an artificial laboratory environment, patients face no risk of adverse local dermal reactions or foreign substance exposure. The CDC notes that the FDA has approved two primary IGRA formulations in the United States: QuantiFERON-TB Gold Plus and the T-SPOT.TB test.

This screening assay supports public health initiatives, occupational health monitoring, and pre-employment medical clearances. It does one job well. Medical providers use the test to detect tuberculosis exposure before latent organisms have an opportunity to progress into active disease. Knowing the biological basis of the assay helps patients understand what their screening results indicate about their exposure history.

How an IGRA Blood Test Works

An interferon-gamma release assay works by incubating whole blood with synthetic peptides that simulate tuberculosis antigens and measuring the resulting immune response. When a phlebotomist draws blood for this test, the sample goes into specialized collection tubes containing distinct chemical preparations. One tube serves as a negative control, containing no antigens, to measure the baseline level of interferon-gamma naturally present in the patient's bloodstream. Another tube contains synthetic peptides designed to mimic specific proteins found in Mycobacterium tuberculosis. A final tube serves as a positive control, using a non-specific stimulant called a mitogen to verify that the patient's immune cells can mount a normal cellular reaction.

During laboratory processing, the blood incubates at controlled body temperatures for several hours. If the patient has had prior exposure to tuberculosis, sensitized T-lymphocytes in the sample recognize the synthetic peptides and secrete interferon-gamma into the liquid plasma. Laboratory technicians then separate the liquid plasma and measure the exact concentration of interferon-gamma using an enzyme-linked immunosorbent assay.

The laboratory compares the interferon-gamma levels across the negative control, the antigen tubes, and the positive control. Subtracting the background baseline from the antigen tube measurement produces the final diagnostic value. This multi-tube control system allows the laboratory to verify sample viability, detect technical errors, and confirm that background inflammation does not generate a false interpretation.

QuantiFERON-TB Gold Test vs. the TB Skin Test

The QuantiFERON-TB Gold test differs from the traditional tuberculin skin test by requiring only a single blood draw and avoiding cross-reactions with prior tuberculosis vaccinations. The traditional tuberculin skin test (TST), often referred to as a purified protein derivative (PPD) test, has served as a standard diagnostic tool for decades. During a skin test, a health care provider injects a small amount of liquid tuberculin PPD solution directly under the top layer of skin on the inner forearm. The patient must return to the clinic 48 to 72 hours later so a trained health worker can examine the forearm, palpate the raised induration, and record the measurement in millimeters.

This two-step schedule creates significant logistical challenges. Patients who fail to return within the mandatory 72-hour window must repeat the entire procedure from the beginning. Furthermore, measuring skin induration involves subjective visual and manual assessment, which can lead to measurement variation between different health workers. In contrast, an IGRA blood draw takes place during a single clinical visit, and the laboratory analyzes the sample using automated, objective instrumentation.

Vaccination history marks another major distinction between the two screening methods. Many individuals born outside the United States have received the bacille Calmette-Guerin (BCG) vaccine, an immunization used globally to protect children against severe tuberculosis complications. Because the standard PPD solution shares biological antigens with the BCG strain, individuals who received the BCG vaccine frequently exhibit false-positive reactions on tuberculin skin tests.

The QuantiFERON-TB Gold test avoids this cross-reactivity problem by using synthetic peptides that do not exist in the BCG vaccine strain or in most environmental non-tuberculous mycobacteria. According to CDC guidance, TB blood tests are the preferred method of tuberculosis testing for people age 5 and older who have received the BCG vaccine. Tuberculin skin tests remain an acceptable clinical option when blood tests are unavailable, technically impractical, or too costly.

What a Positive, Negative, or Indeterminate Result Means

A QuantiFERON-TB Gold test result is classified as positive, negative, or indeterminate based on how the patient's immune cells respond relative to laboratory control standards. A positive result indicates that the concentration of interferon-gamma in the antigen-stimulated tube rose significantly above the baseline control. This outcome means the patient has likely been infected with Mycobacterium tuberculosis at some point in life. However, a positive screening result does not mean that the person has active, contagious disease. It reflects immune memory rather than current clinical illness.

A negative result means that the immune cells did not produce a detectable surge of interferon-gamma when exposed to the tuberculosis peptides. This outcome indicates that tuberculosis infection is unlikely. A negative test cannot completely rule out infection in individuals who experienced very recent exposure, as the immune system typically requires several weeks to develop a measurable cellular response following contact with the bacteria. Severe immune suppression can also blunt cellular responsiveness.

An indeterminate result occurs when the laboratory assay fails to produce a conclusive diagnostic answer. This situation usually happens for one of two biological or procedural reasons. In some cases, the negative control tube demonstrates high baseline levels of interferon-gamma, which reflects preexisting systemic inflammation that obscures any antigen-specific response. In other cases, the positive mitogen control tube fails to produce an adequate immune reaction, which indicates that the patient's white blood cells are impaired or that the sample degraded during transport.

Laboratories calibrate their diagnostic equipment against strict reference thresholds. Reference ranges and cutoff values vary slightly between testing facilities depending on specific platform configurations and analytical methods. Patients should review the quantitative values printed on their own laboratory reports alongside a physician rather than attempting to interpret raw numerical units against generic outside reference sheets.

Latent vs. Active TB Infection

The key clinical distinction in tuberculosis diagnostics is the difference between latent tuberculosis infection and active tuberculosis disease. When a person inhales Mycobacterium tuberculosis, the immune system often mounts a defense that walls off the bacteria inside microscopic structures in the lungs. In individuals with latent tuberculosis infection, the bacteria remain alive inside the body, but they stay contained and dormant. People with latent infection are not sick, experience no physical symptoms, and cannot transmit the bacteria to other people. They can live for decades without the infection ever affecting their daily health.

Active tuberculosis disease develops when the immune system fails to contain the bacteria, which enables the organisms to multiply and spread through tissue. Patients with active pulmonary tuberculosis commonly experience persistent coughing, unexplained weight loss, night sweats, low-grade fevers, and physical exhaustion. Because the bacteria actively damage lung tissue, individuals with active pulmonary or laryngeal disease can spread the infection to others through microscopic respiratory droplets expelled during coughing, speaking, or breathing.

Testing.com emphasizes that screening tests like QuantiFERON-TB Gold cannot distinguish between latent infection and active disease. Both states trigger a cellular immune response that causes sensitized T-cells to release interferon-gamma during laboratory testing. A positive result flags a possible infection. It is a screening milestone. It alerts medical professionals to investigate whether the infection is quiet or actively advancing, rather than confirming active illness on its own.

Who Typically Gets Tested

Tuberculosis screening tests are routinely administered to individuals with high occupational exposure risks, contacts of known cases, and patients preparing for immunosuppressive therapies. Occupational health protocols frequently require tuberculosis screening for health care workers, emergency medical personnel, and laboratory staff. Because these professionals interact with broad patient populations in clinical settings, periodic testing helps prevent institutional transmission and detects occupational exposures early. Facilities often conduct baseline screening upon hire and repeat testing periodically based on regional risk assessments.

Individuals who have shared enclosed living or working spaces with a person diagnosed with active pulmonary tuberculosis also require prompt screening. Public health departments trace close contacts of confirmed cases to identify exposed individuals before dormant bacteria can progress into clinical disease. Routine screening is also common practice in congregate living environments, correctional facilities, and long-term care settings where respiratory pathogens can spread efficiently.

Medical providers also order tuberculosis screening before initiating certain specialized medical treatments. Patients preparing to begin biologic medications, tumor necrosis factor inhibitors, organ transplants, or high-dose corticosteroid regimens routinely undergo IGRA testing. Because these therapies dampen cell-mediated immunity, any undetected latent tuberculosis could reactivate into severe disease if not identified and treated beforehand. Screening ensures that dormant infections are addressed proactively before immunosuppression begins.

What Happens After a Positive QuantiFERON-TB Gold Test

A positive QuantiFERON-TB Gold test requires a systematic clinical workup to rule out active disease before a medical provider recommends a preventive treatment plan. When a patient receives a positive blood test, the immediate clinical priority is determining whether active tuberculosis disease is present. A physician begins with a medical history and a physical examination, and assesses classic symptoms such as prolonged cough, chest pain, fever, and unexplained weight loss. The provider will order a chest X-ray to examine the lung fields for infiltrates, cavities, or calcified granulomas that indicate active or historical pulmonary involvement.

If the chest radiograph shows abnormal findings, or if the patient reports respiratory symptoms, the physician will order microbiological testing. According to Testing.com, diagnostic confirmation involves collecting sputum samples for acid-fast bacilli (AFB) smear microscopy and mycobacterial culture. Sputum cultures take several weeks to grow, but they identify the living organism, confirm active disease, and allow laboratories to test for antibiotic susceptibility.

If the medical evaluation shows no physical symptoms, the chest X-ray is normal, and sputum tests are negative, the patient receives a diagnosis of latent tuberculosis infection. At this point, the clinician will discuss preventive treatment options. Modern preventive regimens use targeted antibiotics, taken over several months to eradicate dormant bacteria and reduce the lifetime risk of reactivation. Completing preventive therapy protects the individual from developing active tuberculosis in the future. If you have questions about your personal risk profile following a QuantiFERON-TB Gold test, consult your physician and consider completing an online health assessment to help guide your clinical discussions.